March 5, 2026Communications Medicine0 citationsOpen Access
Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial
This research aims to evaluate the effectiveness and safety of eribulin combined with gemcitabine for recurrent HER2-negative breast cancer.
Phase II, single-arm, open-label trial design
Participants received eribulin and gemcitabine as second-line treatment
Assessment of treatment efficacy and safety through patient monitoring
Eribulin plus gemcitabine demonstrated effectiveness in managing recurrent HER2-negative breast cancer
Treatment was well-tolerated with minimal severe side effects
Provides a potential second-line treatment option for patients with limited choices
Abstract
Eribulin plus gemcitabine is effective and well-tolerated in patients with HER2-negative metastatic breast cancer needing second-line or later treatment, providing a valuable treatment option.